Transgene SA
TRGNF
$0.70
-$0.89-55.98%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -98.78% | -98.98% | -26.50% | 7.01% | 48.56% |
| Total Other Revenue | 43.02% | 13.68% | -5.86% | -20.77% | -33.42% |
| Total Revenue | 17.46% | -4.49% | -19.54% | -22.86% | -25.79% |
| Cost of Revenue | 25.60% | 19.10% | 15.90% | 7.35% | -1.21% |
| Gross Profit | -27.91% | -26.72% | -28.81% | -19.12% | -9.00% |
| SG&A Expenses | -15.23% | -4.54% | 11.09% | 14.87% | 19.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 164.17% | -98.80% | -102.30% | -103.53% | -104.77% |
| Total Operating Expenses | 16.95% | 12.34% | 10.85% | 4.72% | -1.38% |
| Operating Income | -16.85% | -16.30% | -18.85% | -12.45% | -5.87% |
| Income Before Tax | -61.58% | -54.55% | -52.26% | -4.25% | 29.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.58% | -54.55% | -52.26% | -4.25% | 29.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.58% | -54.55% | -52.26% | -4.25% | 29.14% |
| EBIT | -16.85% | -16.30% | -18.85% | -12.45% | -5.87% |
| EBITDA | -16.95% | -16.91% | -20.04% | -13.59% | -6.97% |
| EPS Basic | -23.30% | -26.08% | -32.74% | 4.29% | 29.87% |
| Normalized Basic EPS | -23.54% | -26.28% | -32.96% | 23.25% | 50.55% |
| EPS Diluted | -25.91% | -27.47% | -32.96% | 5.11% | 31.04% |
| Normalized Diluted EPS | -23.54% | -26.28% | -32.96% | 23.25% | 50.55% |
| Average Basic Shares Outstanding | 30.91% | 23.47% | 15.98% | 8.60% | 1.17% |
| Average Diluted Shares Outstanding | 30.91% | 23.47% | 15.98% | 8.60% | 1.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |